The gold standard, if you will, is being able to have a label on the product that says it’s sterile.

The cardiac rhythm management business is large — $10 billion, highly profitable and it’s an oligopoly.

Obviously, the Guidant board favors the certainty associated with J&J’s offer. They’ve basically gotten the FTC to sign off with J&J. They just need shareholder approval.

The advantage to [metal implants] is that they’re sterile. But the disadvantage is they don’t remodel over time.

If Boston Scientific is to come back, they will have to come back north of US$75 to keep this alive. They’ll have to come back at least US$2 or more higher than they were.

The overall number where there is actually a problem is still low, but more importantly, you’ve got, once again, a revelation that the problem is a little wider than first thought. What people had been...

It seems like Boston Scientific really wants this deal and will pull out all the stops to get it. It’s a very rare asset. Cardiac rhythm management has $10 billion and only three companies.